Desmoteplase for acute ischemic stroke: A systematic review and meta analysis of randomized controlled trials

CNS and Neurological Disorders - Drug Targets

Volumn 16, Issue 7, 2017, Pages 789-799

  Elmaraezy, Ahmed ^a   Abushouk, Abdelrahman Ibrahim ^b   Saad, Soha ^c   Eltoomy, Moutaz ^d   Mahmoud, Osama ^e   Hassan, Hossam Mahmoud ^f   Aboelmakarem, Ahmed ^c   Fotoh, Ahmed Aboel ^g   Althaher, Farah ^h   Huy, Nguyen Tien ^i,j   Hirayama, Kenji ^j  

^a AL AZHAR UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c TANTA UNIVERSITY   (Egypt)

^d UNIVERSITY OF SADAT CITY   (Egypt)

^e Ahmed Maher's Teaching Hospital   (Egypt)

^f BENI SUEF UNIVERSITY   (Egypt)

^g BENHA UNIVERSITY   (Egypt)

^h Misr University for Science and Technology   (Egypt)

ⁱ TON DUC THANG UNIVERSITY   (Viet Nam)

^j NAGASAKI UNIVERSITY   (Japan)

more..

Author keywords

Desmoteplase; Ischemic stroke; Meta analysis; Mortality; Reperfusion; Tissue plasminogen activator

Indexed keywords

DESMOTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR; SALIVARY PLASMINOGEN ACTIVATOR ALPHA 1, DESMODUS ROTUNDUS;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL OUTCOME; DATA EXTRACTION; DATA SYNTHESIS; DIABETES MELLITUS; DRUG SAFETY; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MEAN TRANSIT TIME; META ANALYSIS; MIDDLE CEREBRAL ARTERY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; REPERFUSION; SYSTEMATIC REVIEW; CEREBROVASCULAR ACCIDENT; COMPLICATION; TREATMENT OUTCOME;

BRAIN ISCHEMIA; HUMANS; PLASMINOGEN ACTIVATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 85038443378     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666161213110104     Document Type: Article

References (22)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016; 133: 447.
2. Murray CJL, Barber RM, Foreman KJ, et al Global, regional, and national disability-adjusted life years (dalys) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015; 386: 2145-91.
3. Cheng NT, Kim AS. Intravenous thrombolysis for acute ischemic stroke within 3 hours versus between 3 and 4.5 hours of symptom onset. Neurohospitalist 2015; 5: 101-09.
4. Fugate JE, Rabinstein AA. Absolute and relative contraindications to IV rt-PA for acute ischemic stroke. Neurohospitalist 2015; 5: 110-21.
5. Sahlas DJ, Gould L, Swartz RH, et al. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes. J Stroke Cerebrovasc Dis 2014; 23: 155-59.
6. Kaur J, Zhao Z, Klein GM, et al. The neurotoxicity of tissue plasminogen activator& quest. J Cerebral Blood Flow Metabol 2004; 24: 945-963.
7. Gardell SJ, Ramjit DR, Stabilito II, et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-253.
8. Medcalf RL, Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012; 165:75-89.
9. Mellott MJ, Ramjit DR, Stabilito II, et al. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissuetype plasminogen activator as assessed by a rabbit cuticle bleeding time model. Thromb Haemost 1995; 73: 478-483.
10. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
11. Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS) evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-31.
12. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusiondiffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-150.
13. Albers GW, von Kummer R, Truelsen T, et al. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 2015; 14: 575-584.
14. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of interventions. The Cochrane Collaboration 2008.
15. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997; 315: 629-634.
16. Mori E, Minematsu K, Nakagawara J, et al. Safety and tolerability of desmoteplase within 3 to 9 hours after symptoms onset in japanese patients with ischemic stroke. Stroke 2015; 46: 2549-54.
17. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2014; 7: 4
18. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-09.
19. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Annal Neurol 2006; 60: 508-17.
20. Paciaroni M, Medeiros E, Bogousslavsky. J Desmoteplase Expert Opin Biol Ther 2009; 9: 773-78.
21. Donnan GA, Baron J-C, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009; 8: 261-69.
22. Mishra NK, Albers GW, Davis SM, et al. Mismatch-based delayed thrombolysis a meta-analysis. Stroke 2010; 41: e25-33.